VolitionRx Limited (VNRX)
ASE · Healthcare · Medical Devices
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About VolitionRx Limited
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 627K | 447K | 985K | 399K |
| Operating Income | (4.9M) | (4.7M) | (5.2M) | (4.2M) |
| Net Income | (5.4M) | (6.3M) | (6.7M) | (7.3M) |
| Diluted EPS | $-1.00 | N/A | $-0.97 | $-0.85 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 306K | 775K | 1.2M | 1.7M |
| Operating Income | (30.6M) | (35.8M) | (26.9M) | (21.2M) |
| Net Income | (30.3M) | (35.3M) | (27.0M) | (23.4M) |
| Diluted EPS | $-11.00 | $-10.00 | $-6.20 | $-4.40 |